53391-77-8Relevant academic research and scientific papers
Modified coumarins. 11. Synthesis and biological activity of mannich bases of substituted 2,3-dihydrocyclopenta[c]chromen-4-ones
Garazd,Panteleimonova,Garazd,Khilya
, p. 330 - 336 (2003)
Mannich bases containing the dialkylaminomethyl group in the 6- and 8-positions of 2,3-dihydrocyclopenta[c]chromen-4-ones were prepared by condensation of 7- and 9-hydroxy-2,3-dihydrocyclopenta[c]chromen-4-ones with substituted 1,1-diaminomethanes. The effects of 8-chloro-7-hydroxy-6-(l- pyrrolidinylmethyl)-2,3-dihydrocyclopenta[c]chromen-4-one and 8-chloro-7-hydroxy-6-(morpholinomethyl)-2,3-dihydrocyclopenta[c]chromen-4-one on the central and peripheral nervous system were defined and enable the presence of tranquilizing and neuroleptic properties to be predicted.
Synthesis and evaluation of new coumarin derivatives as potential atypical antipsychotics
Chen, Yin,Lan, Yu,Wang, Songlin,Zhang, Heng,Xu, Xiangqing,Liu, Xin,Yu, Minquan,Liu, Bi-Feng,Zhang, Guisen
, p. 427 - 439 (2014/02/14)
In this paper, we report the synthesis of novel, potential antipsychotic coumarin derivatives combining potent dopamine D2, D3 and serotonin 5-HT1A, 5-HT2A receptors properties. We describe the structure activity relationship that leads us to the promising derivative: 7-(4-(4-(6-fluorobenzo[d]isoxazol-3-yl)piperidin-1-yl)butoxy)-6-methyl-2, 3-dihydrocyclopenta[c]chromen-4(1H)-one 27. The unique pharmacological features of compound 27 are a high affinity for dopamine D2, D3 and serotonin 5-HT1A, 5-HT2A receptors, together with a low affinity for H1 receptor (to reduce the risk of obesity under chronic treatment). In animal models, compound 27 inhibited apomorphine-induced climbing and MK-801-induced hyperactivity without observable catalepsy at the highest dose tested. In particular, compound 27 was more potent than clozapine.
